Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at Svb Leerink issued their Q1 2020 EPS estimates for Hologic in a report released on Friday, April 12th. Svb Leerink analyst R. Newitter anticipates that the medical equipment provider will earn $0.63 per share for the quarter. Svb Leerink also issued estimates for Hologic’s Q2 2020 earnings at $0.64 EPS, Q3 2020 earnings at $0.66 EPS, Q4 2020 earnings at $0.67 EPS and FY2021 earnings at $2.80 EPS.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, January 30th. The medical equipment provider reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.01. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The business had revenue of $830.70 million during the quarter, compared to analysts’ expectations of $823.22 million. During the same quarter in the prior year, the company earned $0.55 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis.

HOLX has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $53.00 price objective for the company in a research report on Tuesday, March 5th. TheStreet upgraded shares of Hologic from a “c” rating to a “b” rating in a research report on Monday, March 4th. Needham & Company LLC restated a “buy” rating and issued a $48.00 price objective on shares of Hologic in a research report on Monday, January 14th. Cowen cut shares of Hologic from an “outperform” rating to a “market perform” rating and set a $38.28 price objective for the company. in a research report on Friday, January 4th. Finally, BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a report on Monday, February 4th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company. Hologic presently has an average rating of “Hold” and an average target price of $44.52.

HOLX opened at $47.04 on Monday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.30 and a quick ratio of 0.91. Hologic has a 12 month low of $35.10 and a 12 month high of $48.82. The firm has a market capitalization of $13.85 billion, a P/E ratio of 21.09, a PEG ratio of 2.22 and a beta of 0.75.

In other Hologic news, Director Sally Crawford sold 12,306 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $47.61, for a total transaction of $585,888.66. Following the completion of the transaction, the director now owns 168,886 shares in the company, valued at approximately $8,040,662.46. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Benjamin Jordan Cohn sold 6,830 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $46.70, for a total value of $318,961.00. Following the completion of the transaction, the insider now owns 22,002 shares of the company’s stock, valued at approximately $1,027,493.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,378 shares of company stock valued at $1,105,836. Corporate insiders own 0.90% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Oregon Public Employees Retirement Fund grew its holdings in shares of Hologic by 3,960.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 1,192,649 shares in the last quarter. Lindbrook Capital LLC bought a new position in shares of Hologic in the 4th quarter valued at about $36,000. Essex Savings Bank bought a new position in shares of Hologic in the 4th quarter valued at about $37,000. Cerebellum GP LLC bought a new position in shares of Hologic in the 4th quarter valued at about $43,000. Finally, Clean Yield Group bought a new position in shares of Hologic in the 4th quarter valued at about $47,000. Institutional investors own 89.91% of the company’s stock.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Trading Strategy Methods and Types

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.